Interleukin 7 upregulates vascular endothelial growth factor D in breast cancer cells and induces lymphangiogenesis in vivo

British Journal of Surgery

Volumn 92, Issue 3, 2005, Pages 305-310

  Al Rawi, M A A ^a   Watkins, G ^a   Mansel, R E ^a   Jiang, W G ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BIOLOGICAL MARKER; INTERLEUKIN 7; LYMPHATIC VESSEL ENDOTHELIAL HYALURONAN RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VON WILLEBRAND FACTOR; MESSENGER RNA; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL STRAIN MCF 7; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LYMPHANGIOGENESIS; METASTASIS; MICROTUBULE; MOUSE; NONHUMAN; NUDE MOUSE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; ANIMAL; BREAST TUMOR; CANCER TRANSPLANTATION; DRUG EFFECT; METABOLISM; METHODOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; INTERLEUKIN-7; LYMPHANGIOGENESIS; MICE; MICE, NUDE; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR D;

EID: 15944366221     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1002/bjs.4832     Document Type: Article

References (35)

1. Forbes JF. The incidence of breast cancer: the global burden, public health considerations. Semin Oncol 1997; 24(Suppl 1): S20-S35.
2. Obermair A, Kurz C, Czerwenka K, Thoma M, Kaider A, Wagner T et al. Microvessel density and vessel invasion in lymph-node-negative breast cancer: effect on recurrence-free survival. Int J Cancer 1995; 62: 126-131.
3. Locopo N, Fanelli M, Gasparini G. Clinical significance of angiogenic factors in breast cancer. Breast Cancer Res Treat 1998; 52: 159-173.
4. Swartz MA, Skobe M. Lymphatic function, lymphangiogenesis, and cancer metastasis. Microsc Res Tech 2001; 55: 92-99.
5. Banerji S, Ni J, Wang SX, Clasper S, Su J, Tammi R et al. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol 1999; 144: 789-801.
6. Breiteneder-Geleff S, Matsui K, Soleiman A, Meraner P, Poczewski H, Kalt R et al. Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis. Am J Pathol 1997; 151: 1141-1152.
7. Wigle JT, Oliver G. Prox1 function is required for the development of the murine lymphatic system. Cell 1999; 98: 769-778.
8. Cunnick GH, Jiang WG, Gomez KF, Mansel RE. Lymphangiogenesis quantification using quantitative PCR and breast cancer as a model. Biochem Biophys Res Commun 2001; 288: 1043-1046.
9. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001; 7: 192-198.
10. Makinen T, Jussila L, Veikkola T, Karpanen T, Kettunen MI, Pulkkanen KJ et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med 2001; 7: 199-205.
11. Kurebayashi J, Otsuki T, Kunisue H, Mikami Y, Tanaka K, Yamamoto S et al. Expression of vascular endothelial growth factor (VEGF) family members in breast cancer. Jpn J Cancer Res 1999; 90: 977-981.
12. Al-Rawi MA, Mansel RE, Jiang WG. Interleukin-7 is a putative lymphangiogenic factor in endothelial cells. Breast Cancer Res Treat 2002; 76(Suppl 1): S166.
13. Al-Rawi MA, Rmali K, Watkins G, Mansel RE, Jiang WG. Aberrant expression of interleukin-7 (IL-7) and its signalling complex in human breast cancer. Eur J Cancer 2004; 40: 494-502.
14. Al-Rawi MA, Rmali K, Mansel RE, Jiang WG. Interleukin 7 induces the growth of breast cancer cells through a wortmannin-sensitive pathway. Br J Surg 2004; 91: 61-68.
15. Parr C, Watkins G, Mansel RE, Jiang WG. The hepatocyte growth factor regulatory factors in human breast cancer. Clin Cancer Res 2004; 10: 202-211.
16. Jussila L, Alitalo K. Vascular growth factors and lymphangiogenesis. Physiol Rev 2002; 82: 673-700.
17. Hu DE, Hori Y, Fan TP. Interleukin-8 stimulates angiogenesis in rats. Inflammation 1993; 17: 135-143.
18. Akagi Y, Liu W, Xie K, Zebrowski B, Shaheen RM, Ellis LM. Regulation of vascular endothelial growth factor expression in human colon cancer by interleukin-1beta. Br J Cancer 1999; 80: 1506-1511.
19. Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 2001; 7: 186-191.
20. Niki T, Iba S, Tokunou M, Yamada T, Matsuno Y, Hirohashi S. Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma. Clin Cancer Res 2000; 6: 2431-2439.
21. George ML, Tutton MG, Janssen F, Arnaout A, Abulafi AM, Eccles SA et al. VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression. Neoplasia 2001; 3: 420-427.
22. Duff SE, Li C, Jeziorska M, Kumar S, Saunders MP, Sherlock D et al. Vascular endothelial growth factors C and D and lymphangiogenesis in gastrointestinal tract malignancy. Br J Cancer 2003; 89: 426-430.
23. Achen MG, Williams RA, Baldwin ME, Lai P, Roufail S, Alitalo K et al. The angiogenic and lymphangiogenic factor vascular endothelial growth factor-D exhibits a paracrine mode of action in cancer. Growth Factors 2002; 20: 99-107.
24. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 2002; 1: 219-227.
25. 5 Partanen TA, Paavonen K. Lymphatic versus blood vascular endothelial growth factors and receptors in humans. Microsc Res Tech 2001; 55: 108-121.
26. Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 2001; 7: 186-191.
27. Veikkola T, Jussila L, Makinen T, Karpanen T, Jeltsch M, Petrova TV et al. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J 2001; 20: 1223-1231.
28. Stricter RM, Kunkel SL, Einer VM, Martonyi CL, Koch AE, Polverini PJ et al. Interleukin-8. A corneal factor that induces neovascularization. Am J Pathol 1992; 141: 1279-1284.
29. Partanen TA, Arola J, Saaristo A, Jussila L, Ora A, Miettinen M et al. VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues. FASEB J 2000; 14: 2087-2096.
30. Makinen T, Jussila L, Veikkola T, Karpanen T, Kettunen MI, Pulkkanen KJ et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med 2001; 7: 199-205.
31. Leu AJ, Berk DA, Lymboussaki A, Alitalo K, Jain RK. Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res 2000; 60: 4324-4327.
32. Akagi K, Ikeda Y, Miyazaki M, Abe T, Kinoshita J, Maehara Y et al. Vascular endothelial growth factor-C (VEGF-C) expression in human colorectal cancer tissues. Br J Cancer 2000; 83: 887-891.
33. Amioka T, Kitadai Y, Tanaka S, Haruma K, Yoshihara M, Yasui W et al. Vascular endothelial growth factor-C expression predicts lymph node metastasis of human gastric carcinomas invading the submucosa. Eur J Cancer 2002; 38: 1413-1419.
34. Crawley JB, Rawlinson L, Lali FV, Page TH, Saldatvala J, Foxwell BM. T cell proliferation in response to interleukins 2 and 7 requires p38MAP kinase activation. J Biol Chem 1997; 272: 15 023-15 027.
35. Xia P, Aiello LP, Ishii H, Jiang ZY, Park DJ, Robinson GS et al. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest 1996; 98: 2018-2826.